BioLight Israeli Life Sciences Investments

What BioLight Israeli Life Sciences Investments does

BioLight Life Sciences Ltd. is an Israeli holding company founded in 2005 and publicly traded on the Tel Aviv Stock Exchange (TASE: BOLT) that invests in and manages a portfolio of companies developing treatments for eye diseases. The company focuses exclusively on ophthalmology and operates approximately 8 portfolio companies spanning medical devices, diagnostics, drug delivery, and digital health — including DiagnosTear's TeaRx tear-based diagnostic platform, ViSci's Eye-D sub-conjunctival Latanoprost implant, OphRx's nanostructure drug delivery, AEYE Health's FDA-approved AI retinal screening, Peripherex's home vision monitoring, Sanoculis's glaucoma surgical procedure, Tarsier Pharma's uveitis drug, and the recently acquired RevitalVision vision-improvement software. BioLight's stated strategy is to address large patient populations (dry eye, glaucoma, diabetic retinopathy, digital eye strain) by leveraging Israeli innovation and a network of global ophthalmology experts and Scientific Advisory Board members anchored by former Teva Pharmaceutical executives and Harvard/Stanford-trained clinicians.

BioLight generates returns primarily through successful portfolio company exits and secondarily through portfolio-level commercial revenue. In 2024 the company completed two material divestitures: the sale of Belkin Vision (an approximately 4% stake) to Alcon as part of a transaction valued at approximately $500 million, generating approximately 9 million NIS plus contingent consideration, and the divestiture of LipiCare (Ocular.D) to Chemipal. The company also benefits from portfolio-level revenue streams including consumer e-commerce sales of Ocular.D via Amazon, diagnostic services through DiagnosTear, a February 2024 exclusive license and research collaboration between OphRx and a global pharmaceutical company, and B2B partnerships including an Alexion/AstraZeneca clinical research collaboration and clinical trials with LV Prasad Eye Institute in India. Distribution spans direct-to-consumer e-commerce, B2B pharmaceutical licensing, and healthcare-provider channels.

Management is led by CEO Yaacov Michlin (former Brainsway CEO who led its NASDAQ IPO) and Chairman Israel Makov (former President & CEO of Teva Pharmaceutical Industries). The board and Scientific Advisory Board include former senior Teva, AbbVie, and Johnson & Johnson executives alongside internationally recognized ophthalmologists. BioLight ended 2021 with total assets of approximately NIS 143.5 million, raised an additional 20 million NIS through a public shares-and-warrants offering in September 2025, and is currently consolidating ViSci and OphRx under the Ocuvia umbrella for a planned U.S. stock exchange listing while affiliated Tarsier Pharma pursues a NYSE IPO.

Name

BioLight Israeli Life Sciences Investments

Legal name

BioLight Life Sciences Ltd.

Website

https://bio-light.co.il

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

BioLight Life Sciences Ltd. is an Israeli publicly traded holding company that invests in and manages an ophthalmology-focused portfolio of diagnostics, drug delivery, medical device, and digital health companies targeting dry eye, glaucoma, diabetic retinopathy, and other eye diseases.

Ownership category

akta.pro rank

Product category

Ophthalmology Investment Holding

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Offices of Optometrists (62132)

SIC

Ophthalmic Goods (3851), Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

akta.pro secondary industries

Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Ophthalmology investment holding
• Eye care medical devices
• Ocular drug delivery
• Ophthalmic diagnostics
• Eye disease treatments

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Investment Returns and Exit Proceeds: BioLight generates returns through successful exits of portfolio companies (Belkin Vision sold to Alcon for ~$500M, LipiCare sold to Chemipal) and value creation in held companies.
2. Portfolio Company Revenue: Some portfolio companies generate revenue from product sales (Ocular.D commercial product), diagnostic services, and licensing agreements.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

BioLight Life Sciences Ltd. is a publicly traded Israeli holding company that invests in, manages, and commercializes biomedical innovations exclusively in the field of ophthalmology. The company operates through a diversified portfolio of majority-owned and affiliated companies developing medical devices, diagnostics, drug delivery technologies, and digital medicine for eye diseases, generating returns through exits, licensing, royalties, and portfolio company revenues.

Product overview

BioLight Life Sciences Ltd. is a holding company that invests solely in ophthalmology, operating through portfolio companies that develop advanced medical devices, pharmaceuticals, diagnostics, and digital health solutions. The portfolio includes: DiagnosTear's TeaRx™ tear-based diagnostic platform (CE-IVD approved for dry eye); ViSci's Eye-D (VS-101) sub-conjunctival implant for glaucoma; OphRx's nanostructure-based drug delivery; LipiCare's Ocular D nano-emulsion eye drops with Vitamin D; AEYE Health's AI-based retinal disease diagnostics (FDA approved); Peripherex home vision monitoring; Belkin Vision's automatic laser device; Sanoculis' surgical procedure for glaucoma; and Tarsier Pharma's uveitis treatment. The company also invested in RevitalVision for vision improvement software. BioLight maintains 8 portfolio companies with 2 completed exits (Belkin Vision sold to Alcon, LipiCare sold to Chemipal).

Differentiator

Problem solved

Functional benefit

Brands

• Ocuvia: Planned merged entity combining ViSci and OphRx subsidiaries, developing nano-droplet drug delivery (ocudrip) and sustained-release implant (ocugrid) platforms for ocular therapies.

Products and services

• TeaRx™ (DiagnosTear) A diagnostic platform for point-of-care testing of ophthalmic pathologies through multi-parameter composition analysis of tear fluid. The first CE-IVD approved test is for identification and monitoring of Dry Eye Syndrome (DES), for use by eye care professionals and ophthalmology clinics.
• Eye-D (VS-101) by ViSci A sub-conjunctival implant that releases Latanoprost in a sustained-release manner to treat glaucoma, eliminating the need for daily eye drops. Developed for ophthalmologists and glaucoma patients.
• Ocular D by LipiCare A nano-emulsion eye drop product with integrated Vitamin D that filters blue light, providing relief from digital eye strain and dry eye symptoms. Marketed to consumers and eye care professionals.
• OphRx Nano-Delivery Platform An innovative technological platform using nanostructures to enhance the transmission of active substances for treating eye diseases. Currently developing 0.5% Cyclosporine formulation for dry eye syndrome. Targeted at pharmaceutical partners and ophthalmology clinics.
• AEYE Health AI Diagnostics AI-based diagnosis solutions for retinal diseases, including autonomous screening for diabetic retinopathy and diabetic macular edema. FDA approved for both desktop and portable devices. For healthcare providers and eye care professionals.
• Peripherex At-home diagnosis and monitoring solutions for peripheral vision impairment using eye tracking software on any personal computer or tablet with built-in camera. FDA registered. For glaucoma patients and eye care providers.
• Belkin Vision Eagle Laser Device Automatic, clinic-fast laser device for primary treatment of glaucoma that enables patients to receive short and effective treatments to reduce intraocular pressure (IOP). FDA approved. For ophthalmologists and glaucoma clinics.
• Sanoculis Surgical Procedure Innovative surgical procedure for the treatment of glaucoma. Received additional CE marketing approval in Europe for mild-to-moderate glaucoma indication. For ophthalmic surgeons and hospitals.
• Tarsier Pharma TRS 01 Bio-inspired medical solution for treatment of uveitis in patients with high intraocular pressure (IOP). Late clinical-stage development with positive Phase III results in the US. For ophthalmologists and uveitis specialists.
• Ocuvia (Planned Merger) A planned merger of ViSci and OphRx under the Ocuvia umbrella, combining ocudrip (nano-droplet technology) and ocugrid (sub-conjunctival implant platform) for sustained drug release in chronic eye conditions. For ophthalmic pharmaceutical partners.
• RevitalVision Vision improvement software for digital medicine in eye health. For eye care professionals and patients with vision impairments.

Quantifiable outcome

• TeaRx Dry Eye achieved over 80% sensitivity for severe dry eye detection
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Global Pharmaceutical Company (OphRx)coreStrategic or Co-development Partner · 29 February 2024OphRx (55% owned) entered agreement with a global pharmaceutical company for research collaboration and option for exclusive license for drug based on OphRx technology.
• Sheba Medical CentercoreStrategic or Co-development Partner · 21 September 2023BioLight collaborated with Sheba Medical Center to discover a new drug in development aimed to prevent blindness. Sheba is Israel's largest medical center with renowned ophthalmology department.
• Alexion (AstraZeneca Rare Disease)coreStrategic or Co-development Partner · 29 May 2023BioLight entered clinical research collaboration with Alexion to evaluate screening technique for retinal ophthalmic conditions. The collaboration focuses on developing innovative technology based on natural tears for diagnosis of retinal diseases.
• Bausch + LombcoreChannel Partner/ Reseller/ Distributor · 28 July 2022Bausch + Lomb and Sanoculis announced strategic agreements designed to address unmet needs in glaucoma. Sanoculis is BioLight's portfolio company developing an innovative surgical procedure for glaucoma treatment.
• LV Prasad Eye InstitutecoreStrategic or Co-development PartnerLV Prasad Eye Institute in India partnered with DiagnosTear for clinical trials of TeaRx Red Eye product for allergic conjunctivitis, herpetic keratitis, and adenoviral conjunctivitis.
• Maccabi Health ServicesminorStrategic or Co-development PartnerDr. Ron Neumann serves as special consultant in inflammatory eye disease to Maccabi, Israel's leading Health Maintenance Organization.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Bausch + Lomb: Bausch + Lomb is one of the largest global eye health companies with a broad portfolio of pharmaceuticals, surgical devices, and consumer vision care. Comparable as a former strategic distribution partner for BioLight's Sanoculis subsidiary.
• Carl Zeiss Meditec: Carl Zeiss Meditec is a leading global medical technology company specializing in ophthalmology and optometry solutions including diagnostic devices, surgical microscopes, and laser systems. Comparable as a broad incumbent serving similar ophthalmology customer segments as BioLight's portfolio.
• Alcon: Alcon is the global leader in eye care, offering surgical and vision care products across pharmaceuticals, devices, and consumer health. Comparable as the acquirer of BioLight's Belkin Vision portfolio company, indicating strategic fit between BioLight's portfolio and Alcon's M&A strategy.

Direct peers

• Oculis: Oculis is a clinical-stage biopharmaceutical company focused on ophthalmology, developing novel treatments for retinal and front-of-eye diseases. Comparable as a pure-play ophthalmology therapeutics developer with portfolio of multiple candidates targeting dry eye, DME, and other ocular conditions.
• EyePoint Pharmaceuticals: EyePoint Pharmaceuticals is a specialty pharmaceutical company focused on ophthalmic therapeutics using sustained-release drug delivery technologies. Comparable as a developer of ophthalmology drug delivery platforms targeting similar conditions to BioLight's ViSci and OphRx subsidiaries.
• Glaukos Corporation: Glaukos is an ophthalmic medical technology company focused on novel interventional therapies for glaucoma. Comparable as a developer of innovative ophthalmic devices and drug delivery platforms, similar to BioLight's Belkin Vision, Sanoculis, and ViSci holdings.
• Ocular Therapeutix: Ocular Therapeutix is a biopharmaceutical company developing therapies for eye diseases using proprietary hydrogel technology for sustained drug delivery. Comparable as an ophthalmology drug delivery specialist addressing dry eye, glaucoma, and other retinal conditions.
• Aerie Pharmaceuticals: Aerie Pharmaceuticals was a clinical-stage ophthalmology pharmaceutical company developing treatments for glaucoma and dry eye (now part of Alcon). Comparable as a pure-play ophthalmology pharma with portfolio of differentiated drug delivery technologies for glaucoma.
• Nicox: Nicox is a France-based ophthalmology specialty pharmaceutical company developing treatments for ocular conditions including glaucoma and dry eye. Comparable as a pure-play ophthalmology specialty pharma with similar therapeutic focus areas to BioLight's portfolio.

Regional players

• Laboratoires Théa: Laboratoires Théa is a European independent pharmaceutical company specializing in ophthalmology, with a portfolio of eye drops, surgical products, and diagnostic solutions. Comparable as a specialty ophthalmology pharma with similar therapeutic focus, primarily serving European markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCWQ0pPjz7IoUgkTXbfyybZw
• LinkedInlinkedin.com/company/bio-light

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries5 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioLight Israeli Life Sciences Investments